Impact of oral semaglutide on cardiovascular risk factors in patients with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease: a SOUL post hoc analysis
Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.